Olmesartan
As of the edition of 20 October 2026, Olmesartan is a small molecule: marketed, first approved in 2003 (ES); acts on AGTR1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2017
- Kind
- Small molecule
- Brand name
- Olmetec
- First approved
- 10 July 2003 (ES)
- Approvals on record
- 4 in 3 regions
- Holder of the most recent approval
- TORRENT DO BRASIL LTDA; 4 holders in all
- Registered trials
- 28, 3 stopped early
- Disease areas
- Heart and blood vessels; Nutrition and metabolism; Hormones; Infections; Lungs and airways; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Olmesartan.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | P30556 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 5 | 0 | 0 |
| Phase 1 | 4 | 3 | 0 | 0 |
| Phase 2 | 3 | 2 | 0 | 0 |
| Phase 3 | 9 | 6 | 0 | 1 |
| Phase 4 | 6 | 3 | 0 | 2 |
| All trials | 28 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 2005 to now |